Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials

The benefit of adding Zolbetuximab to the treatment in patients with Claudin-18 isoform 2 (CLDN18.2)-positive, human epidermal growth factor receptor 2-negative, locally advanced unresectable or metastatic gas...

Source: BMC Cancer - February 21, 2024 Category: Cancer & Oncology Authors: Francisco Cezar Aquino de Moraes, Eric Pasqualotto, Matheus Pedrotti Chavez, Rafael Oliva Morgado Ferreira, Tiago Biachi De Castria and Rommel Mario Rodr íguez Burbano Tags: Research Source Type: research